Geode Capital Management LLC Has $5.77 Million Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Geode Capital Management LLC lifted its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 12.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 715,570 shares of the company's stock after acquiring an additional 79,488 shares during the quarter. Geode Capital Management LLC owned 0.20% of Bausch Health Companies worth $5,767,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of BHC. Tobam boosted its stake in Bausch Health Companies by 10.4% during the 4th quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after acquiring an additional 1,422 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Bausch Health Companies by 10.6% during the fourth quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock worth $220,000 after purchasing an additional 2,600 shares during the last quarter. Blair William & Co. IL grew its stake in Bausch Health Companies by 3.2% in the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after purchasing an additional 2,622 shares in the last quarter. Sanders Morris Harris LLC grew its position in shares of Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Kendall Capital Management increased its stake in Bausch Health Companies by 43.4% during the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company's stock valued at $145,000 after purchasing an additional 5,445 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Companies Price Performance

BHC traded down $0.15 on Thursday, hitting $5.16. The company had a trading volume of 585,687 shares, compared to its average volume of 2,692,283. The company's fifty day moving average price is $6.14 and its 200 day moving average price is $7.26. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -42.87, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, sell-side analysts forecast that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BHC shares. Jefferies Financial Group reissued a "hold" rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Royal Bank of Canada lowered their target price on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a report on Monday, April 7th. Finally, StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Thursday. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $7.17.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.